Investigational drug · Phase 3
allo-APZ2-OTS
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epidermolysis Bullosa.
Phase 3Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "allo-APZ2-OTS"
First trial start
2023
Jun 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "allo-APZ2-OTS", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidermolysis Bullosa
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "allo-APZ2-OTS" as an intervention, largest first.
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)Pivotal-lookingActive, not recruiting
RHEACELL GmbH & Co. KGIndustry
NCT05464381 · 91 participants · Start Jun 13, 2023 · Primary completion Aug 29, 2025
Drug: allo-APZ2-OTS; Placebo · For: Epidermolysis Bullosa
Sites: Buenos Aires, Argentina; Salzburg, Austria; Santiago, Chile · 16 sites in all
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)Pivotal-lookingActive, not recruiting
RHEACELL GmbH & Co. KGIndustry
NCT05838092 · 9 participants · Start Oct 18, 2023 · Primary completion Aug 29, 2025
Drug: allo-APZ2-OTS; Placebo · For: Epidermolysis Bullosa
Sites: Aurora, Colorado; Minneapolis, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Epidermolysis Bullosa
- pz-celEB-101 Surgical application of RDEB woundsPhase 31 trial
Abeona Therapeutics, Inc · Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.